Logo image of BLCO

BAUSCH + LOMB CORP (BLCO) Stock Price, Quote, News and Overview

NYSE:BLCO - New York Stock Exchange, Inc. - CA0717051076 - Common Stock - Currency: USD

11.5  -0.09 (-0.78%)

After market: 11.5 0 (0%)

BLCO Quote, Performance and Key Statistics

BAUSCH + LOMB CORP

NYSE:BLCO (5/2/2025, 8:04:01 PM)

After market: 11.5 0 (0%)

11.5

-0.09 (-0.78%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Supplies
Statistics
52 Week High21.69
52 Week Low10.45
Market Cap4.06B
Shares353.36M
Float41.58M
Yearly DividendN/A
Dividend YieldN/A
PE23.96
Fwd PE12.45
Earnings (Next)N/A N/A
IPO05-06 2022-05-06


BLCO short term performance overview.The bars show the price performance of BLCO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

BLCO long term performance overview.The bars show the price performance of BLCO in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30

The current stock price of BLCO is 11.5 USD. In the past month the price decreased by -11.47%. In the past year, price decreased by -15.44%.

BAUSCH + LOMB CORP / BLCO Daily stock chart

BLCO Competitors/Peers

The largest stocks on the US markets in the "Health Care Supplies" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ALC ALCON INC 32.23 49.12B
COO COOPER COS INC/THE 21.83 16.46B
ALGN ALIGN TECHNOLOGY INC 19.27 13.16B
SOLV SOLVENTUM CORP 10.11 11.70B
LNTH LANTHEUS HOLDINGS INC 16.04 7.45B
MMSI MERIT MEDICAL SYSTEMS INC 26.8 5.65B
ICUI ICU MEDICAL INC 22.77 3.49B
HAE HAEMONETICS CORP/MASS 15.09 3.21B
XRAY DENTSPLY SIRONA INC 8.43 2.81B
UFPT UFP TECHNOLOGIES INC 26.61 1.55B
NEOG NEOGEN CORP 15.13 1.25B
ESTA ESTABLISHMENT LABS HOLDINGS N/A 965.30M

About BLCO

Company Profile

BLCO logo image Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 13,500 full-time employees. The company went IPO on 2022-05-06. The company operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.

Company Info

BAUSCH + LOMB CORP

520 Applewood Crescent

Vaughan ONTARIO CA

Employees: 13300

BLCO Company Website

BLCO Investor Relations

Phone: 19082552864

BAUSCH + LOMB CORP / BLCO FAQ

What is the stock price of BAUSCH + LOMB CORP today?

The current stock price of BLCO is 11.5 USD. The price decreased by -0.78% in the last trading session.


What is the ticker symbol for BAUSCH + LOMB CORP stock?

The exchange symbol of BAUSCH + LOMB CORP is BLCO and it is listed on the New York Stock Exchange, Inc. exchange.


On which exchange is BLCO stock listed?

BLCO stock is listed on the New York Stock Exchange, Inc. exchange.


What is the price forecast or stock price prediction for BAUSCH + LOMB CORP stock?

19 analysts have analysed BLCO and the average price target is 18.78 USD. This implies a price increase of 63.33% is expected in the next year compared to the current price of 11.5. Check the BAUSCH + LOMB CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BAUSCH + LOMB CORP worth?

BAUSCH + LOMB CORP (BLCO) has a market capitalization of 4.06B USD. This makes BLCO a Mid Cap stock.


How many employees does BAUSCH + LOMB CORP have?

BAUSCH + LOMB CORP (BLCO) currently has 13300 employees.


What are the support and resistance levels for BAUSCH + LOMB CORP (BLCO) stock?

BAUSCH + LOMB CORP (BLCO) has a resistance level at 13.34. Check the full technical report for a detailed analysis of BLCO support and resistance levels.


Is BAUSCH + LOMB CORP (BLCO) expected to grow?

The Revenue of BAUSCH + LOMB CORP (BLCO) is expected to grow by 4.73% in the next year. Check the estimates tab for more information on the BLCO EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BAUSCH + LOMB CORP (BLCO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BAUSCH + LOMB CORP (BLCO) stock pay dividends?

BLCO does not pay a dividend.


What is the Price/Earnings (PE) ratio of BAUSCH + LOMB CORP (BLCO)?

The PE ratio for BAUSCH + LOMB CORP (BLCO) is 23.96. This is based on the reported non-GAAP earnings per share of 0.48 and the current share price of 11.5 USD. Check the full fundamental report for a full analysis of the valuation metrics for BLCO.


What is the Short Interest ratio of BAUSCH + LOMB CORP (BLCO) stock?

The outstanding short interest for BAUSCH + LOMB CORP (BLCO) is 4.85% of its float. Check the ownership tab for more information on the BLCO short interest.


BLCO Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

BLCO Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to BLCO. BLCO has a medium profitability rating, but doesn't score so well on its financial health evaluation.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BLCO Financial Highlights

Over the last trailing twelve months BLCO reported a non-GAAP Earnings per Share(EPS) of 0.48. The EPS decreased by -32.39% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -2.35%
ROE -4.9%
Debt/Equity 0.73
Chartmill High Growth Momentum
EPS Q2Q%-200%
Sales Q2Q%3.46%
EPS 1Y (TTM)-32.39%
Revenue 1Y (TTM)11.94%

BLCO Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 73% to BLCO. The Buy consensus is the average rating of analysts ratings from 19 analysts.

For the next year, analysts expect an EPS growth of 7.48% and a revenue growth 4.73% for BLCO


Ownership
Inst Owners10.12%
Ins Owners0.28%
Short Float %4.85%
Short Ratio2.78
Analysts
Analysts72.63
Price Target18.78 (63.3%)
EPS Next Y7.48%
Revenue Next Year4.73%